Sino Biopharm stock fell 1.99 percent on October 7

Published on 10/08/2026 at 02:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sino Biopharm stock reported RMB 19.44 billion in first-half revenue, up 10.6 percent year over year. Innovation and licensing revenue reached RMB 8.79 billion, up 44.3 percent.

Sino Biopharm, KYG8167W1380, Illustration mit AI erstellt.

Sino Biopharm (ISIN KYG8167W1380) fell 1.99 percent in the October 7, 2026, Hong Kong session, putting the latest market move alongside a first-half revenue increase of 10.6 percent. The company trades as 1177.HK on HKEX under the stated ISIN, as Global Banking and Finance identifies it.

Revenue reaches RMB 19.44 billion

For the six months ended June 30, 2026, Sino Biopharm recorded revenue of RMB 19.44 billion, up 10.6 percent from the prior-year period, according to Moomoo.

Profit attributable to equity holders reached RMB 3.43 billion, an increase of 1.4 percent, while underlying profit rose 8.1 percent to RMB 3.34 billion. After excluding Sinovac Biotech dividend income, underlying profit increased 92.3 percent to RMB 1.74 billion, making the adjustment material to the comparison, Moomoo reported.

Innovation revenue reaches RMB 8.79 billion

Innovative-medicine and out-licensing revenue reached RMB 8.79 billion in the first half of 2026, up 44.3 percent year over year and equal to 45.2 percent of total revenue. Innovative-medicine revenue contributed RMB 7.81 billion, up 29.2 percent, while licensing revenue was RMB 980 million, up 2,101.9 percent.

The mix gives pipeline execution and licensing timing a larger role in the earnings profile than the headline revenue growth alone suggests. The board also announced an interim dividend of HKD 0.07 per share for the period, according to Moomoo.

Stock remains below HKD 8.54 high

Sino Biopharm stock was last at HKD 5.67 on HKEX on October 7, 2026, at 4:08 p.m. HKT, with volume of 33,224,123 shares. Its 52-week range was HKD 4.19 to HKD 8.54, while market capitalization stood at HKD 101.1 billion on the same date.